Type 2 diabetes drug empagliflozin
Draft guidance recommends empagliflozin for treating type 2 diabetes after preliminary appraisal last August. NICE called for more evidence to demonstrate that empagliflozin was a good use of NHS resources compared with other already available treatments. Boehringer Ingelheim submitted a new cost effectiveness model showing that empagliflozin combination therapy is a cost effective treatment option for some people with type 2 diabetes.
Boehringer Ingelheim provided new evidence to allow us to recommend empagliflozin as a treatment option for some people with type 2 diabetes giving more choice to get the right treatment for them.
Until final guidance is issued, NHS bodies should make decisions locally on the funding of specific treatments. …more